Patents by Inventor Paula Marie Cannon

Paula Marie Cannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6620595
    Abstract: The invention provides novel retroviral vectors that have enhanced transcription termination structures. The termination structures comprise one or several heterologous upstream transcription termination enhancer (UE) sequences, or one or more additional copies of endogenous UE sequences operably associated with the 3′ LTR polyadenylation signal. The retroviral vectors of the invention have various improved properties over conventional vectors, including stronger gene expression, enhanced vector titer and reduced interference with host cell gene expression resulting from read-through of vector initiated transcriptional events.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: September 16, 2003
    Assignee: University of Southern California
    Inventors: Paula Marie Cannon, Maria Barcova
  • Publication number: 20020042136
    Abstract: The invention provides novel retroviral vectors that have enhanced transcription termination structures. The termination structures comprise one or several heterologous upstream transcription termination enhancer (UE) sequences, or one or more additional copies of endogenous UE sequences operably associated with the 3′ LTR polyadenylation signal. The retroviral vectors of the invention have various improved properties over conventional vectors, including stronger gene expression, enhanced vector titer and reduced interference with host cell gene expression resulting from read-through of vector initiated transcriptional events.
    Type: Application
    Filed: May 14, 2001
    Publication date: April 11, 2002
    Inventors: Paula Marie Cannon, Maria Barcova
  • Patent number: 6168916
    Abstract: A method of making retrovirus vectors having selected characteristics, in particular an increased ability to infect a particular target cell, comprises subjecting a starting retrovirus or retroviral vector to a selection process in vitro which involves a plurality of rounds of infection of a host cell during which the retrovirus or retroviral vector evolves to attain the selected characteristics. Components of the evolved retrovirus or retroviral vector can be used in retroviral vector production systems for producing retroviral vectors having the selected characteristics. The invention is particularly useful for preparing retroviral vectors suitable for gene therapy.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: January 2, 2001
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan John Kingsman, Susan Mary Kingsman, Paula Marie Cannon, Martin Andreas Nowak
  • Patent number: 6096538
    Abstract: A DNA construct is disclosed which comprises a packagable retroviral genome operably linked to a first promotor, wherein the retroviral genome comprises a 5' long terminal repeat (5' LTR) which includes sequences encoding R and U3 regions and 3' long terminal repeat (3' LTR) which includes sequences encoding R and U3 regions, and wherein at least said R regions of the 5' LTR and 3' LTR are identical to each other and are different from those of the retrovirus on which the retroviral genome is based. The DNA constructs are useful in the production of packaged retroviruses.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: August 1, 2000
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan John Kingsman, Susan Mary Kingsman, Paula Marie Cannon